|
General populations
|
|
Europe [26]
|
> 2.2 mmol/L
|
23.0% (8316/36,160)
|
TG > 2.2 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified)
|
6.0% (2169/36,160)
|
|
On statin [26]
|
> 2.2 mmol/L
|
30.0% (10,848/36,160)
| | |
|
USA [28, 30]
|
|
Not on statin
|
≥ 2.26 mmol/L
|
11.9% (21.5 M/181.0 M)*
|
TG ≥ 2.26 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified)
|
6.6% (13.1 M/199.1 M)*
|
|
On statin
|
≥ 2.26 mmol/L
|
15.4% (6.0 M/38.9 M)*
| | |
|
High risk populations
|
|
Primary prevention + risk factors [31]
|
≥ 2.3 mmol/L
|
20.8% (1591/7641)
|
Elevated TG + HDL-C < 1.0 mmol/L
|
9.9% (759/7641)
|
|
With T2DM [31]
|
≥ 2.3 mmol/L
|
27.5% (562/2046)
|
Elevated TG + HDL-C < 1.0 mmol/L
|
14.9% (305/2046)
|
|
Clinical ASCVD [29, 32]
|
> 1.7 mmol/L
|
34.7% (2938/8467)
|
TG > 2.0 mmol/L + HDL-C < 1.0 mmol/L in men, < 1.2 mmol/L in women
|
13–14%**
|
